-
5X Protein Loading Buffer (Reducing) Guide
2026-09-23
5X Protein Loading Buffer (Reducing) prepares protein samples for conventional reducing SDS-PAGE by combining SDS, a sulfhydryl reducing agent, buffer salts, and a tracking dye. Use it when denaturation and disulfide-bond reduction are appropriate; do not use it for native analysis or workflows that need to preserve non-reduced disulfide patterns.
-
BFH772 (VEGFR2 inhibitor) Protocol Guide
2026-09-23
BFH772 is a selective small-molecule VEGFR2 kinase tool for testing VEGFR2-dependent signaling and angiogenesis in biochemical, cellular, and tumor-model workflows. It is suited to organic-solvent stock preparation but should not be selected for water-based formulations or interpreted as a broad-spectrum kinase inhibitor without additional counter-screening.
-
H2S, Persulfidation, and Ferroptosis in NSCLC
2026-09-22
A 2024 Molecular Cell study shows that hydrogen sulfide sensitizes non-small cell lung cancer cells to ferroptosis during cystine depletion by persulfidating S-adenosyl homocysteine hydrolase. This modification reduces homocysteine production, limits cysteine and glutathione availability, and provides a mechanistic rationale for combining hydrogen sulfide activity with ferroptosis-based therapies.
-
METTL16–SENP3–LTF Axis in HCC Ferroptosis
2026-09-22
Wang et al. identify a METTL16–SENP3–LTF signaling axis that protects hepatocellular carcinoma cells from iron-dependent lipid peroxidation and supports tumor progression. The study connects m6A-regulated RNA stability with SUMO-dependent protein turnover and iron sequestration, providing a mechanistic framework for sensitizing HCC to ferroptosis-based interventions.
-
Lisinopril Dihydrate: ACE Assay Interpretation
2026-09-21
Lisinopril dihydrate is a long-acting ACE inhibitor whose value in cardiovascular and renal models depends on interpreting direct enzyme inhibition alongside downstream renin–angiotensin readouts. This article presents an assay-centered framework, grounded in comparative peptidase evidence, for improving mechanistic confidence and reproducibility.
-
Carvedilol Phosphate: A New Lens on Hepatic IRI
2026-09-21
A translational strategy for using Carvedilol Phosphate as a defined adrenergic perturbation in hepatic ischemia–reperfusion studies, anchored to the Arrb2–6-ketoLCA–macrophage axis while separating established evidence from exploratory hypotheses.
-
CCK8, NOX4, and ANP Secretion in Rat Atria
2026-09-20
The reference study identifies a signaling mechanism by which sulfated cholecystokinin octapeptide stimulates ANP secretion in isolated beating rat atria. Its results connect fatty-acid signaling, NOX4-derived hydrogen peroxide, PGC-1α, and PPARα/PPARγ activation, while also revealing feedback regulation by ANP.
-
Saquinavir Workflows for HIV Protease Research
2026-09-19
Use Saquinavir as a controlled HIV protease inhibitor benchmark for enzymatic, cellular, and membrane-interaction studies. A biomimetic chromatography workflow helps separate target-enzyme activity from permeability behavior, supporting more informative antiretroviral drug research and exploratory cancer research.
-
Aminopeptidase Selectivity in ACE Inhibitor Studies
2026-09-18
Tieku and Hooper’s 1992 study directly compared inhibitor activity across aminopeptidases A, N, and W, revealing that commonly assumed selectivity patterns—especially for bestatin—were not reliable. The findings show why enzyme-panel controls are essential when interpreting ACE inhibitor experiments, peptide metabolism, and cardiovascular or renal disease models.
-
EZ Cap™ CBEmax mRNA: Fidelity-First Design
2026-09-18
EZ Cap™ CBEmax mRNA (m1Ψ) supports transient cytosine base-editing research, but meaningful results depend on guide selection, controls, and off-target analysis. This article translates whole-genome evidence into a practical assay framework distinct from embryo-production case studies.
-
Angiotensin I Workflows for RAS Research
2026-09-17
Build reproducible Angiotensin I conversion, cell-signaling, and drug-screening assays with practical controls for peptide stability and matrix effects. A data-quality framework inspired by fluorescence classification research helps separate genuine biological signals from analytical interference without overstating cross-domain evidence.
-
Angiotensin Peptides and SARS-CoV-2 Spike–AXL Binding
2026-09-17
Oliveira et al. report that selected naturally occurring angiotensin peptides enhance antibody-detected binding between the SARS-CoV-2 spike protein and AXL, with some shorter or N-terminally modified peptides showing greater activity than angiotensin II. The work provides a mechanistic link between renin-angiotensin signaling and viral receptor biology while emphasizing that binding enhancement must be distinguished from proven effects on infection or disease.
-
Angiotensin 1/2 (2-7) Research Workflows
2026-09-16
Use Angiotensin 1/2 (2-7) as a defined peptide input for renin-angiotensin signaling pathway studies, vascular-response assays, and receptor-binding experiments. Its short sequence also provides a practical bridge to emerging work on angiotensin-modulated SARS-CoV-2 spike–receptor interactions.
-
Resazurin Cell Viability Assay Kit Workflow
2026-09-16
Build a sensitive, non-destructive cell viability assay around resazurin reduction, with practical guidance for screening, dose-response studies, and mechanistic oncology workflows. This article translates findings from parthenolide-treated lymphoid malignancy models into assay design, controls, troubleshooting, and orthogonal validation strategies.
-
Angiotensin I Workflows for RAS Research
2026-09-15
Turn Angiotensin I into a controlled substrate for ACE activity studies, antihypertensive drug screening, and cardiovascular mechanism experiments. This practical guide combines peptide handling, assay controls, neuroendocrine study design, and a data-quality lesson from fluorescence spectroscopy research.